#health systems #Switzerland #Novo Nordisk #Geneva #WHO Foundation

WHO Foundation and Novo Nordisk Enhance Their Collaboration

On March 11, 2026, the WHO Foundation announced an expanded collaboration with Novo Nordisk, designed to bolster global health systems in addressing the growing burdens of cardiovascular, kidney, and metabolic disorders, including obesity and diabetes. Novo Nordisk has committed a total of $7.9 million for this collaborative effort; initially contributing $2.9 million in 2024, followed by an additional $5 million slated for December 2025.

This partnership aims to support the WHO's overarching strategy of combating non-communicable diseases through prevention, early intervention, and improved primary healthcare, particularly in low- and middle-income countries where healthcare systems often face significant challenges.

Anil Soni, CEO of the WHO Foundation, emphasized the complexity of heart, kidney, and metabolic diseases, which necessitate preventive approaches entrenched in robust and resilient health systems. He stated, “By supporting the WHO’s leadership in prevention, we can strengthen the scientific and health policy frameworks that countries need to respond effectively and equitably.”

Elin Jäger, Senior Vice President for Corporate Strategy & Sustainability at Novo Nordisk, added, “The fight against obesity, diabetes, and related conditions requires a comprehensive partnership—collaboration among governments, communities, civil society, and the private sector to promote prevention, early detection, and care. By increasing Novo Nordisk’s contribution to the WHO Foundation, we hope to equip more countries with the tools, insights, and resources they need for effective local action.”

Global Context of Obesity

Amidst rising health concerns globally, obesity has reached epidemic levels. More than one billion individuals worldwide are living with obesity, which includes 650 million adults, 340 million adolescents, and 39 million children. Since 1975, obesity rates have nearly tripled worldwide, and overweight and obesity are now responsible for more deaths globally than being underweight. Alarmingly, 39 million children under the age of five are overweight or obese, while over 340 million individuals aged between 5 and 19 are also affected by these conditions.

The WHO Foundation, established in 2020 and headquartered in Geneva, Switzerland, operates as an independent entity to support the mission of the World Health Organization (WHO). It mobilizes philanthropic funding and forges strategic partnerships aimed at promoting health equity, addressing urgent health issues, and strengthening lifesaving systems. By connecting partners and healthcare professionals, the Foundation facilitates the dissemination of proven solutions, funds life-saving measures, and drives sustainable changes towards achieving ‘health for all’. More information can be found at WHO Foundation.

In conclusion, the collaboration between the WHO Foundation and Novo Nordisk marks a significant step forward in addressing the complex challenges posed by non-communicable diseases. With comprehensive strategies, increased funding, and a unified approach, this partnership endeavors to enhance the resilience of health systems globally, ensuring that health inequities are addressed and that communities are better equipped to manage health crises effectively.